Table 1.
Adverse events.
| Grade | ||||
|---|---|---|---|---|
| Adverse event, n (%) | G1 | G2 | G3 | G4 |
| Blood and lymphatic system disorders | ||||
| Eosinophilia | 1 (7%) | |||
| Febrile neutropenia | 1 (7%) | |||
| Hemolysis | 1 (7%) | |||
| Cardiac disorders | ||||
| Chest Pain | 2 (13%) | |||
| Hypotension | 1 (7%) | |||
| Endocrine disorders | ||||
| Hypothyroidism | 1 (7%) | |||
| Eye disorders | ||||
| Photophobia | 1 (7%) | |||
| Gastrointestinal disorders | ||||
| Abdominal Pain | 1 (7%) | |||
| Diarrhea | 3 (20%) | 2 (13%) | ||
| Distension/bloating, abdominal | 1 (7%) | |||
| Gastroesophageal reflux disease | 1 (7%) | |||
| Mucositis/stomatitis | 1 (7%) | |||
| Nausea | 1 (7%) | |||
| Sore Throat | 1 (7%) | |||
| Vomiting | 1 (7%) | |||
| Oral Pain | 1 (7%) | |||
| General disorders and administration site conditions | ||||
| Edema Limbs | 1 (7%) | |||
| Fatigue | 1 (7%) | 1 (7%) | ||
| Flu like symptoms | 1 (7%) | 1 (7%) | ||
| Infections and infestations | ||||
| Upper respiratory infection | 2 (13%) | |||
| Lung Infection | ||||
| Sepsis | 1 (7%) | |||
| Investigations | ||||
| Alanine aminotransferase increased | 2 (13%) | 1 (7%) | 1 (7%) | |
| Aspartate aminotransferase increased | 1 (7%) | |||
| Musculoskeletal and connective tissue disorders | ||||
| Arthralgia | 1 (7%) | |||
| Back Pain | 1 (7%) | |||
| Nervous system disorders | ||||
| Dizziness | 2 (13%) | |||
| Respiratory, thoracic, and mediastinal disorders | ||||
| Pneumonitis | 2 (13%) | |||
| Cough | 1 (7%) | |||
| Allergic Rhinitis | 1 (7%) | |||
| Cough | 1 (7%) | |||
| Hemoptysis | 1 (7%) | |||
| Nasal Congestion | 1 (7%) | |||
| Skin and subcutaneous tissue disorders | ||||
| Hyperpigmentation | 1 (7%) | |||
| Pruritus/itching | 4 (27%) | 1 (7%) | ||
| Rash | 1 (7%) | |||